Zynex Inc. Liquidates Shares in Chapter 11 Reorg—Insiders Sell Zero‑Priced Stakes

Corporate Reorganization and Shareholder Implications: The Case of Zynex Inc.

Zynex Inc. completed the liquidation of all outstanding shares on March 26, 2026, as part of a Chapter 11 reorganization plan. The transaction, executed by director Barry D. Michaels, involved the sale of 80,001 shares at a price of $0.00. This action effectively wiped the company’s share count and cancelled all equity awards. The plan’s effectiveness was confirmed in the company’s 15‑12G filing, which also terminated its common‑stock registration. With the stock now delisted, any holdings that investors held are either voided or, if they had purchased new shares issued to the plan sponsor, subject to a new capital structure.

Insider Sales Reflect a Systemic Reset

On the same day, insiders Disbrow Joshua R. and Cress Michael D. each sold 12,499 restricted shares and, respectively, 89,501 or 82,501 unrestricted shares, all at a zero price. These large‑scale liquidations, coupled with the director’s own sale, suggest that the reorganization was not merely a procedural reset but an active divestiture of pre‑bankruptcy holdings. The zero pricing aligns with the cancellation clause in the plan, which forgoes any consideration for pre‑plan shares. Thus, insiders are acknowledging that the old equity structure has ceased to exist and that any future ownership will stem from the new issuance under the plan sponsor’s terms.

Investor Impact and Future Prospects

From an investor’s standpoint, the immediate effect is a total loss of any pre‑plan stake; no cash or shares will be recovered. The company’s valuation collapse—its 52‑week low of $0.02 and a year‑over‑year decline of 97.27 %—underscores the severity of the situation. However, the reorganization could unlock a new capital base and operational focus. The company is now listed on the OTC Bulletin Board; its future depends on whether the plan sponsor’s newly issued common stock will attract institutional support or whether the company will remain illiquid on the OTC market.

Key indicators—such as the current sentiment score of –68 and a buzz level of 200 %—point to heightened investor unease and media scrutiny. This environment could pressure the company to accelerate a recovery strategy or consider a secondary listing. Until the plan sponsor clarifies issuance terms and any potential listing upgrade, the company’s future remains uncertain.

Summary

Zynex’s Chapter 11 closure and the complete cancellation of its former shares mark the end of one chapter and the uncertain beginning of another. Insider sales at zero price confirm the voiding of pre‑bankruptcy equity, while the lack of subsequent trading activity indicates a cautious, restructuring‑focused approach. Investors must weigh the risk of continued illiquidity against the possibility that a fresh equity issuance under the plan sponsor could provide a new platform for growth in the health‑care equipment sector.